RxDoctor Payments DataLook up a doctor →

Rekha Pillai, MD

Neurology · Memphis, TNNPI 1356318752

Payments from drug & device makers

$354,871in general payments, 2019–2025

Across 707 payments — averaging $501.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$252K
  • Adamas Pharmaceuticals, Inc.$72K
  • Sanofi$17K
  • Genentech USA, Inc.$6K
  • EMD Serono, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$1,80011%
  • Speaking & faculty fees$5,24133%
  • Food & beverage$8,71855%
  • Education$530%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$354,871 in reported general payments places this provider in the 90th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$58,178
Medicare patients
328
Services billed
2,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab12$637,629
OcrevusOcrelizumab12$483,471
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5027$212,747
Avonex Pen (4 Pack)Interferon Beta-1a13$183,294
CopaxoneGlatiramer Acetate25$159,834
BetaseronInterferon Beta-1b14$140,089
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$125,810
Plegridy PenPeginterferon Beta-1a14$111,089
TysabriNatalizumab13$106,736
Dimethyl Fumarate55$88,275
RytaryCarbidopa/Levodopa43$52,294
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$46,738
Nurtec OdtRimegepant Sulfate37$43,134
Dalfampridine ErDalfampridine89$33,957
Aimovig AutoinjectorErenumab-Aooe13$15,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris, Brilinta$176$642,26023 claims
CSL BehringPrivigen$164$212,74727 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,262$159,83425 claims
BiogenTysabri$700$106,73613 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$164$53,52255 claims
PfizerNurtec Odt$39$43,13437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 361 neurology providers in Tennessee.

Other neurology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →